Everyone locked and loaded???, page-29

Yes I agree. I actually had low to mid 30s in mind myself for SPL in the event that AZ unexpectedly terminate the Phase 1 trial.

Questions about the bonafides of the 3 internal DEP drug trials will remain until Phase 2 is complete, results are shared with the market and a commercial deal of substance is signed. Until then, IMO Jackie Fairley is just keeping shareholders on the hook for just a little while longer.

My favourite Jackie Fairley quote from July 2018:

Tom Piotrowski: ”So when you look out over the next 6 months, what are going to be the important milestones for Starpharma?”

Jackie Fairley: “On the DEP side of things, completion of our Phase 2 trial for Dep-Docetaxel.”

Meanwhile, almost FIVE years later ….

This is what we’re dealing with here people! Beware and DYOR with regard to Starpharma.

In any other organisation on the planet, I think you will find this CEO would have been sacked long ago.